We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over $11 billion in sales; Mounjaro ... OrbiMed, Logos Capital, Lilly Asia Ventures, and Lyfe Capital.

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...